Literature DB >> 9626350

VEGF, bFGF and EGF in the angiogenesis of human melanoma xenografts.

T Danielsen1, E K Rofstad.   

Abstract

Vascular endothelial growth factor (VEGF) is a major inducer of angiogenesis in tumors. Basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) have both been shown to interact with VEGF. The involvement of VEGF, bFGF, and EGF in melanoma angiogenesis was investigated here. Four human melanoma cell lines (A-07, D-12, R-18, U-25) were included in the study. Angiogenesis was quantified by scoring of tumor-oriented capillaries following intradermal cell inoculation in BALB/c nu/nu mice. VEGF, bFGF and EGF expression and secretion were investigated by Western blotting and enzyme-linked immunosorbent assay, respectively. Immunohistochemistry of xenografts grown intradermally was used to reveal VEGF and bFGF localization in vivo. The rate of angiogenesis differed substantially among the melanoma lines; the sequence from a high to low rate of angiogenesis was: A-07, D-12, R-18, U-25. A-07, which induced the highest rate of angiogenesis, showed a higher rate of VEGF secretion, stronger VEGF staining by immunohistochemistry and higher bFGF expression than the other lines. U-25, which induced the lowest rate of angiogenesis, showed a higher rate of VEGF secretion than D-12 and R-18. A-07 was the only line that showed detectable bFGF secretion, and R-18 was the only line that showed detectable EGF secretion. VEGF is probably important in the angiogenesis of melanomas. However, heterogeneity in rate of angiogenesis among melanomas cannot be attributed to heterogeneity in rate of secretion of VEGF, bFGF and/or EGF only.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626350     DOI: 10.1002/(sici)1097-0215(19980610)76:6<836::aid-ijc12>3.0.co;2-0

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

Review 1.  Angiogenesis and melanoma.

Authors:  J P Dutcher
Journal:  Curr Oncol Rep       Date:  2001-07       Impact factor: 5.075

Review 2.  The role of the microenvironment in tumor growth and invasion.

Authors:  Yangjin Kim; Magdalena A Stolarska; Hans G Othmer
Journal:  Prog Biophys Mol Biol       Date:  2011-06-28       Impact factor: 3.667

3.  RhoC GTPase overexpression modulates induction of angiogenic factors in breast cells.

Authors:  K L van Golen; Z F Wu; X T Qiao; L Bao; S D Merajver
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

4.  Angiogenesis a putative new approach in glutamine related therapy.

Authors:  P Maity; S Chakraborty; P Bhattacharya
Journal:  Pathol Oncol Res       Date:  1999       Impact factor: 3.201

5.  X box-binding protein 1 regulates angiogenesis in human pancreatic adenocarcinomas.

Authors:  Lorenzo Romero-Ramirez; Hongbin Cao; Maria Paz Regalado; Neeraja Kambham; Dietmar Siemann; Jeff J Kim; Quynh T Le; Albert C Koong
Journal:  Transl Oncol       Date:  2009-03       Impact factor: 4.243

Review 6.  Molecular targeting of liposomal nanoparticles to tumor microenvironment.

Authors:  Gang Zhao; B Leticia Rodriguez
Journal:  Int J Nanomedicine       Date:  2012-12-28

Review 7.  Diet phytochemicals and cutaneous carcinoma chemoprevention: A review.

Authors:  Siliang Wang; Peiliang Shen; Jinrong Zhou; Yin Lu
Journal:  Pharmacol Res       Date:  2017-02-24       Impact factor: 10.334

8.  F-Prostaglandin receptor regulates endothelial cell function via fibroblast growth factor-2.

Authors:  Margaret C Keightley; Pamela Brown; Henry N Jabbour; Kurt J Sales
Journal:  BMC Cell Biol       Date:  2010-01-21       Impact factor: 4.241

9.  Peptide ligand and PEG-mediated long-circulating liposome targeted to FGFR overexpressing tumor in vivo.

Authors:  Lulu Cai; Xianhuo Wang; Wenwen Wang; Neng Qiu; Jiaolin Wen; Xingmei Duan; Xia Li; Xiang Chen; Li Yang; Zhiyong Qian; Yuquan Wei; Lijuan Chen
Journal:  Int J Nanomedicine       Date:  2012-08-14

Review 10.  Molecular Targeted Therapy Approaches for BRAF Wild-Type Melanoma.

Authors:  Romany A N Johnpulle; Douglas B Johnson; Jeffrey A Sosman
Journal:  Curr Oncol Rep       Date:  2016-01       Impact factor: 5.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.